Davis Polk advised the underwriters in connection with an initial public offering of 4,983,333 shares of common stock of Sienna Biopharmaceuticals, Inc., including shares sold pursuant to the full exercise of the underwriters’ over-allotment option, at $15.00 per share, for total gross proceeds of $74.7 million. Sienna Biopharmaceuticals’ common stock is traded on the NASDAQ Global Select Market under the symbol “SNNA.”

Headquartered in Westlake Village, California, Sienna Biopharmaceuticals is a clinical-stage biopharmaceutical company focused on bringing innovations in biotechnology to the discovery, development and commercialization of first-in-class, targeted, topical products in medical dermatology and aesthetics. 

The Davis Polk corporate team included partner Alan F. Denenberg and associates Jason Bassetti and Leeann Overstreet. Counsel Michelle Ontiveros Gross and associate Jason J. Bang provided intellectual property and technology advice. Partner Rachel D. Kleinberg, associate Karen Li and former associate Mahalia S. Burford provided tax advice. Counsel Marcie A. Goldstein provided FINRA advice. Members of the Davis Polk team are based in the Northern California and New York offices.

Copy link to share post